Vasectomy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (Conventional, Minimally Invasive, No-Scalpel), By Patient (Animal, Human), By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 23.11 Billion
CAGR (2026-2031)	7.77%
Fastest Growing Segment	Conventional
Largest Market	North America
Market Size (2031)	USD 36.21 Billion

Market Overview

The Global Vasectomy Market will grow from USD 23.11 Billion in 2025 to USD 36.21 Billion by 2031 at a 7.77% CAGR. Vasectomy is a surgical procedure for male sterilization designed to provide permanent contraception by obstructing the vas deferens, thereby preventing sperm from entering the seminal stream. The market is primarily supported by the procedure's superior cost-effectiveness relative to female sterilization methods and the increasing utilization of minimally invasive no-scalpel techniques, which significantly reduce recovery time. This growing acceptance is substantiated by recent operational data; according to NHS England Digital, in 2024, the total volume of vasectomy procedures performed across Sexual and Reproductive Health services in England reached 22,775 for the fiscal year, reflecting a robust procedural uptake.

Despite this positive trajectory, market expansion is significantly impeded by persistent cultural stigmas and psychological barriers regarding masculinity and sexual potency. These deep-seated misconceptions, coupled with the weight of the procedure's intended permanence, create substantial hesitation among prospective patients who fear regret or physiological changes. Consequently, the lack of effective educational outreach to counter these myths limits broader market penetration, particularly in conservative regions where information regarding the safety and distinct nature of the surgery remains insufficient.

Key Market Drivers

Increasing male participation in family planning is acting as a primary catalyst for market growth, fundamentally shifting the burden of contraception from being solely a female responsibility. This trend is characterized by a significant demographic expansion, as younger men increasingly opt for sterilization in response to changing reproductive rights landscapes and a desire for shared contraceptive accountability. This sociological shift is quantitatively evident in recent clinical data; according to the American Urological Association, May 2024, in research presented at the '2024 Annual Meeting', the proportion of vasectomy patients under the age of 30 rose significantly to 9.8% of all procedures post-legal changes in the United States. Such demographic broadening ensures a sustained influx of new patients, reducing the market's historical reliance on older cohorts who have completed their families.

Simultaneously, the rising demand for permanent contraception solutions is being accelerated by government initiatives and the active involvement of non-governmental organizations in improving procedure accessibility. These entities are crucial in dismantling cost barriers and normalizing the procedure through subsidized care and educational campaigns, thereby converting latent interest into actual surgical volumes. The scale of this surging demand is illustrated by national health metrics; according to NHS England Digital, September 2024, in the 'Sexual and Reproductive Health Services, England - 2023-24' report, the number of vasectomy procedures performed witnessed a dramatic year-on-year increase of 113%. Furthermore, specific organizational outreach continues to service this growing need; according to the Planned Parenthood Federation of America, in 2024, the organization provided care to 5,388 vasectomy clients, underscoring the critical role of accessible service providers in meeting the expanding global requirement for effective male sterilization.

Download Free Sample Report

Key Market Challenges

Cultural Stigmas and Psychological Barriers

Market expansion is significantly impeded by persistent cultural stigmas and psychological barriers regarding masculinity and sexual potency. These deep-seated misconceptions, coupled with the weight of the procedure's intended permanence, create substantial hesitation among prospective patients who fear regret or physiological changes. Many men equate fertility with virility, leading to the unfounded belief that vasectomy acts as a form of castration or diminishes sexual performance. This psychological resistance remains a primary restraint on the market, particularly in conservative regions where male dominance in reproductive decision-making is culturally entrenched.

Despite the procedure's proven clinical success, these fears continue to limit broader adoption. The disconnect between public perception and medical reality is evident in recent clinical data. According to the British Association of Urological Surgeons, in 2024, the rate of late procedural failure was reported to be just 1 in 2,000, with significant chronic pain affecting only 1-2% of patients. However, the persistence of myths regarding failure and side effects overshadows these favourable statistics, causing the global uptake of vasectomy to lag significantly behind female sterilization methods.

Key Market Trends

Biotech firms are actively advancing the commercialization of non-hormonal, polymer-based occlusives to establish a new market segment for reversible male sterilization. This innovation directly addresses the psychological barrier of permanence by utilizing injectable hydrogels that block sperm transport without severing the vas deferens, offering a flexible alternative to traditional ligation. The clinical viability of this technology is rapidly progressing; according to Femtech Insider, April 2025, results presented at the American Urological Association meeting confirmed that the 'ADAM' hydrogel system achieved a critical milestone, with two participants in the first-in-human trial demonstrating sustained azoospermia and safety at the 24-month mark.

Simultaneously, a cultural shift driven by digital health advocacy is effectively dismantling historical stigmas surrounding the procedure, rebranding it as a responsible lifestyle choice. Influencers and patient testimonials on social media platforms are normalizing male sterilization, thereby accelerating demand among demographics previously hesitant to engage with reproductive health services. This destigmatization is translating into measurable market growth; according to Population Connection, March 2025, recent analyses indicate that the surge in public interest has compounded clinical demand, with a notable study highlighting that young men utilized vasectomy services at a rate 95% higher than prior baselines in response to the evolving reproductive landscape.

Segmental Insights

Based on recent market analysis, the Conventional segment is identified as the fastest-growing category within the Global Vasectomy Market, primarily driven by its widespread accessibility and cost-effectiveness in emerging economies. This traditional scalpel-based method remains the dominant standard of care in developing nations, where government-sponsored population control initiatives and public healthcare systems prioritize affordable, established surgical protocols. Furthermore, the extensive availability of surgeons already trained in conventional techniques ensures rapid adoption rates in high-population regions. Consequently, the segment is experiencing robust expansion as it meets the rising demand for permanent contraception where advanced, resource-intensive alternatives are less feasible.

Regional Insights

North America holds a leading position in the global vasectomy market due to the high adoption rate of permanent contraception methods among the male population. The region benefits from established healthcare infrastructure and favorable reimbursement policies that improve patient access to these procedures. Furthermore, the U.S. Food and Drug Administration (FDA) ensures a structured regulatory environment, facilitating the safe approval and commercialization of medical devices. This market strength is supported by consistent public awareness regarding family planning and the presence of key manufacturers within the region.

Recent Developments

• In April 2025, NEXT Life Sciences announced the successful completion of its clinical trial in Australia for Plan A, a long-lasting and reversible male contraceptive. The company reported a 100% success rate for the trial, which evaluated a proprietary delivery method for its hydrogel technology, Vasalgel. This non-hormonal product is designed to act as a flexible filter within the vas deferens to block sperm flow for up to ten years while allowing for reversibility. The Chief Executive Officer of NEXT Life Sciences stated that the trial validated the company's approach and delivery system, marking a significant step toward regulatory submission and market launch.
• In April 2025, Contraline reported positive 24-month safety and efficacy results from the first-in-human clinical trial of its ADAM hydrogel. The study, conducted in Australia, demonstrated that the implantable, non-permanent male contraceptive successfully maintained azoospermia (the absence of sperm) in participants over the two-year period with no serious adverse events. The company highlighted that the hydrogel, which is injected into the vas deferens to occlude sperm transport, offers a reversible alternative to traditional vasectomy. Following these results, Contraline received regulatory approval to initiate a Phase 2 early feasibility study to further assess the device's performance.
• In October 2024, Legacy, a digital fertility clinic, and Posterity Health, a male reproductive healthcare provider, entered into a strategic partnership to create an integrated care model for male fertility and contraception. The collaboration combines Posterity Health’s services, which include vasectomies and vasectomy reversals performed by specialized urologists, with Legacy’s at-home sperm testing and cryopreservation kits. This partnership aims to streamline the patient journey by allowing men to preserve sperm prior to undergoing a vasectomy, ensuring future fertility options are secured before the permanent procedure. The executives of both companies emphasized that this alliance would improve access to comprehensive reproductive care and support men in proactive family planning.
• In July 2024, Signati Medical announced the completion of patient enrollment for its Investigational Device Exemption (IDE) clinical trial evaluating the Signati Separo Vessel Sealing System. The trial was designed to assess the safety and efficacy of the company's proprietary bipolar radiofrequency device, which is intended to perform a "sealed vasectomy procedure" without the use of a scalpel or traditional ligation clips. The company aims to demonstrate that this new electrosurgical tool can reduce procedure times and improve patient recovery compared to standard vasectomy techniques. The data collected from this study is intended to support a marketing submission to the U.S. Food and Drug Administration.

Key Market Players

• Pfizer Inc
• Bristol Myers Squibb SA
• Teva Pharmaceuticals USA Inc
• Upsher-Smith Laboratories Inc
• SMITHFIELD BIOSCIENCE
• Opocrin SPA
• Bioiberica SA
• GSK PLC
• Johnson & Johnson Consumer Inc
• Fresenius SE & Co KGaA

By Type	By Patient	By End-User	By Region
Conventional Minimally Invasive No-Scalpel	Animal Human	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Vasectomy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vasectomy Market, By Type:

• Conventional
• Minimally Invasive
• No-Scalpel

• Vasectomy Market, By Patient:

• Animal
• Human

• Vasectomy Market, By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Vasectomy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE